Previous product
Back to products
Gavreto (pralsetinib)
CHF17,615.00
Next product
Tukysa (tucatinib)
CHF3,224.92
Retevmo (selpercatinib)
CHF15,720.75
Retevmo (selpercatinib) is a medication used for the treatment of lung and thyroid cancers with a genetic mutation or fusion in the RET gene. It is the first treatment option available for patients with an abnormal RET gene.
Reviews
There are no reviews yet.